🫗 Hepatic Encephalopathy Lactulose Titration Simulator

The West Haven Criteria — Staging the Continuum of Hepatic Encephalopathy

Hepatic encephalopathy (HE) is a spectrum of neuropsychiatric dysfunction arising from liver failure and/or portosystemic shunting, ranging from subtle attentional deficits detectable only by psychometric testing to deep coma. The West Haven Criteria remain the most widely used bedside grading system, guiding both severity assessment and treatment intensity — from outpatient lactulose titration to ICU-level airway protection.

• 30–40%: Cirrhotics who develop overt HE (lifetime risk)
• 20–80%: Minimal HE prevalence (of cirrhotics, testing-dependent)
• >50%: 1-yr mortality, Grade III–IV (without transplant)
• minutes: Ammonia crosses BBB (as un-ionized NH3)

The West Haven grading scale

Grade 0 (Minimal / covert HE): • No clinically detectable personality or behavioral changes • Abnormalities only on psychometric or neurophysiological testing (PHES battery, critical flicker frequency) • Impairs driving safety and quality of life despite being clinically silent

Grade I (Mild): • Trivial lack of awareness, shortened attention span, mild euphoria or anxiety • Sleep-wake cycle reversal (insomnia at night, hypersomnia by day) is often the earliest overt sign • Mild asterixis may be elicitable

Grade II (Moderate): • Lethargy or apathy, disorientation to time, obvious personality change • Inappropriate behavior, slurred speech • Asterixis readily present (flapping tremor on wrist extension)

Grade III (Severe): • Somnolence to semi-stupor, but responsive to verbal stimuli • Marked confusion, gross disorientation to time and place • Rigidity, hyperreflexia; asterixis usually absent because patient cannot cooperate

Grade IV (Coma): • Unresponsive to verbal and painful stimuli • Decorticate or decerebrate posturing may be present • Airway protection (intubation) usually required

Grade III–IV HE is a medical emergency: it mandates urgent search for a precipitant, airway assessment, and often ICU admission — lactulose alone is insufficient and enteral/rectal routes must be secured.

Pathophysiology — ammonia, astrocytes, and the glutamine hypothesis

The liver normally clears ammonia (NH3), a byproduct of protein/amino acid catabolism and colonic bacterial urease activity, via the urea cycle in hepatocytes. In cirrhosis, two mechanisms converge to raise systemic ammonia:

• Reduced hepatocyte mass and function: less functional urea cycle capacity • Portosystemic shunting: blood bypasses the liver via varices or a TIPS, delivering gut-derived ammonia directly to systemic circulation

Un-ionized NH3 freely crosses the blood-brain barrier within minutes. Astrocytes — the only brain cell type expressing glutamine synthetase — detoxify ammonia by converting glutamate + NH3 → glutamine. This glutamine accumulation is osmotically active, driving astrocyte swelling (low-grade cerebral edema), which impairs astrocyte-neuron signaling, disrupts oscillatory network activity, and produces the clinical picture of HE — from subtle slowing to coma.

Ammonia is necessary but not sufficient: plasma ammonia correlates only moderately with HE grade, because inflammation, oxidative stress, and neurosteroid/GABAergic tone (partly ammonia-independent) also modulate cerebral function — which is why precipitant identification (Stage 2) is as important as ammonia-lowering therapy itself.

Finding and Treating the Trigger — Why Overt HE Is Rarely Spontaneous

Except in advanced end-stage liver disease, an episode of overt HE is usually precipitated by an identifiable, reversible insult. Systematically searching for and correcting this trigger is as important as ammonia-lowering therapy — treating lactulose alone while missing an underlying GI bleed or infection leads to treatment failure and recurrence.

• ~90%: Episodes with identifiable trigger (of overt HE presentations)
• 15–20g: Protein per 100mL blood (GI bleed = large ammonia load)
• 10–30%: SBP prevalence in decompensation (always tap the ascites)
• 1.2–1.5 g/kg: Recommended daily protein intake (do NOT restrict protein)

Common precipitants — the systematic search

Gastrointestinal bleeding: • Variceal or peptic ulcer hemorrhage delivers a massive nitrogenous/protein load (15–20g protein per 100mL blood) to the gut, fueling bacterial ammoniagenesis • Always perform rectal exam / check for melena and hemoglobin trend

Infection: • Spontaneous bacterial peritonitis, urinary tract infection, pneumonia, cellulitis • Cytokine-mediated increase in blood-brain barrier permeability amplifies ammonia neurotoxicity independent of ammonia level itself • Any decompensated cirrhotic with altered mentation warrants diagnostic paracentesis

Constipation: • Prolonged colonic transit increases bacterial contact time and ammonia generation/absorption • Simple, common, and easily corrected

Dehydration / diuretic overuse: • Volume depletion (from over-diuresis, vomiting, diarrhea) reduces renal ammonia excretion and precipitates a hepatorenal-like physiology • Check for hyponatremia, elevated BUN/creatinine

Sedatives and benzodiazepines: • Directly potentiate GABAergic tone, synergizing with HE-related neuroinhibition • Avoid in cirrhotic patients when possible; if sedation required, prefer agents with minimal hepatic metabolism

Electrolyte disturbance: • Hypokalemia and metabolic alkalosis stimulate renal tubular ammoniagenesis and shift the NH4+/NH3 equilibrium toward the CNS-penetrant NH3 form

TIPS placement: • Iatrogenic portosystemic shunting reduces hepatic ammonia clearance; post-TIPS HE occurs in ~30–35% of patients

Dietary protein restriction is an outdated and harmful practice. Current AASLD/EASL guidance recommends normal-to-high protein intake (1.2–1.5 g/kg/day, favoring vegetable/dairy protein) because malnutrition and sarcopenia independently worsen HE and mortality in cirrhosis.

Lactulose — First-Line Ammonia-Lowering Therapy via Colonic Acidification

Lactulose (β-galactosidofructose), a synthetic non-absorbable disaccharide, has been the cornerstone of HE therapy for over 50 years. Unmetabolized by human enzymes, it reaches the colon intact, where bacterial fermentation drives both a cathartic effect and a chemical "ammonia trap" that lowers systemic ammonia delivery.

• 25 mL PO: Initial dose (q1–2h until first BM)
• 2–3: Maintenance target (soft stools per day)
• <6: Colonic pH after fermentation (favors NH4+ trapping)
• 70–80%: Overt HE resolution rate (with adequate titration)

Mechanism of action — three simultaneous effects

1. Ammonia trapping (the dominant mechanism): • Colonic bacteria (Bifidobacteria, Lactobacilli) ferment lactulose into lactic acid and acetic acid • This acidifies the colonic lumen (pH drops from ~7 to <6) • At low pH, the chemical equilibrium NH3 + H+ ⇌ NH4+ shifts toward NH4+ • NH4+ is charged and cannot cross the colonic mucosa (unlike lipophilic NH3), so it is trapped in the lumen and excreted

2. Osmotic cathartic effect: • Lactulose is osmotically active and undigested, drawing water into the colon • Increased stool frequency mechanically flushes ammonia and nitrogenous waste before absorption • This is why stool frequency (not simply "giving the drug") is the titration endpoint

3. Prebiotic flora shift: • Fermentation favors saccharolytic, non-ureolytic bacterial species over proteolytic, urease-producing species • Reduces the colonic bacterial ammonia-generating capacity over sustained use

Dosing protocol: • Acute overt HE: 25mL (range 15–45mL) PO every 1–2 hours until first bowel movement • Once catharsis achieved: reduce frequency, titrate to 2–3 soft (not watery) stools per day • Typical maintenance: 15–30mL PO BID–TID, individualized

Titrating Lactulose Safely — Avoiding the Over-Titration Trap

Lactulose has a narrow therapeutic window between under-dosing (persistent ammonia load, ongoing HE) and over-dosing (dehydration, electrolyte derangement, and paradoxical worsening of encephalopathy). Careful bedside titration against stool output and mental status is required, and alternative routes are needed for patients who cannot safely swallow.

• 2–3/day: Target stool frequency (Bristol type 5–6, soft)
• >4–6/day: Over-titration diarrhea (triggers dose reduction)
• 300mL lactulose: Retention enema volume (in 700mL water, 30–60min)
• majority: Grade III–IV requiring enema/NG (due to dysphagia/aspiration risk)

The over-titration paradox

Excessive lactulose dosing produces watery diarrhea (>4–6 stools/day), which causes:

• Dehydration and hypovolemia — reduces renal perfusion and thus renal ammonia excretion capacity • Hypernatremia or hyponatremia depending on fluid losses and free water intake • Volume depletion can precipitate a hepatorenal-syndrome-like picture, and paradoxically WORSEN encephalopathy despite "more" lactulose being given • Perianal skin breakdown and patient intolerance, reducing adherence

Bedside titration principle: dose to effect (2–3 soft stools/day), not to a fixed volume. Reassess daily in the acute setting; ask specifically about stool frequency and consistency (Bristol Stool Scale types 5–6 are the target), not just "did you have a bowel movement."

Alternative delivery routes for severe HE

Grade III–IV HE, or any patient with dysphagia/aspiration risk or reduced consciousness, cannot safely take oral lactulose:

• Lactulose retention enema: 300mL lactulose diluted in 700mL water, administered via rectal balloon catheter and retained 30–60 minutes with the patient positioned in left lateral decubitus with hips elevated; repeated q4–6h as needed • Nasogastric tube administration: for intubated or severely obtunded patients with a protected/secured airway, standard oral dosing given via NG tube • Enemas are especially valuable because they deliver lactulose directly to the site of action (the colon) and do not require intact swallowing or gastric emptying

Mental status and stool response should be reassessed at least every 4–6 hours during acute titration; failure to improve raises suspicion for an unaddressed precipitant (Stage 2) rather than simply "more lactulose."

Rifaximin — Secondary Prophylaxis for Recurrent Hepatic Encephalopathy

For patients who breakthrough or recur despite adequate lactulose titration and adherence, guidelines recommend adding rifaximin, a minimally-absorbed rifamycin-class antibiotic that reduces the colonic burden of ammoniagenic, urease-producing bacteria. Combination lactulose + rifaximin is now the standard of care for secondary prophylaxis after a second HE episode.

• 550mg PO BID: Rifaximin dose (minimally absorbed, <0.4% F)
• 58%: HE breakthrough reduction (Bass et al. NEJM 2010, HR≈0.42)
• ~50%: HE-related hospitalization reduction (vs placebo, on lactulose)
• ≥2nd episode: Indication threshold (of overt HE on lactulose)

Mechanism and pivotal trial evidence

Rifaximin is a non-systemic, gut-selective antibiotic derived from rifampin, with oral bioavailability under 0.4% — meaning it acts almost entirely within the gut lumen with minimal systemic exposure, drug interactions, or resistance-selection pressure elsewhere in the body.

Mechanism: • Broad-spectrum activity against gram-positive and gram-negative, aerobic and anaerobic enteric bacteria • Selectively suppresses urease-producing (ureolytic) and other ammoniagenic bacterial populations in the colon • Reduces the substrate supply for bacterial ammonia and other gut-derived neurotoxin production, complementing lactulose's acidification/catharsis mechanism

Pivotal evidence — Bass et al., NEJM 2010: • Randomized, double-blind, placebo-controlled trial of rifaximin 550mg BID vs placebo, added to lactulose, in patients with ≥2 prior HE episodes • Primary endpoint (breakthrough HE episode) occurred in 22% of rifaximin patients vs 46% of placebo (hazard ratio 0.42, 58% relative risk reduction) • HE-related hospitalization also significantly reduced (~50% relative reduction)

Current guideline positioning (AASLD/EASL): rifaximin is add-on therapy to lactulose, not a substitute — it is indicated for secondary prophylaxis after a second episode of overt HE while the patient remains on lactulose, and is continued indefinitely absent transplant or major clinical change.

Rifaximin + lactulose combination therapy is now first-line secondary prophylaxis: it substantially outperforms either agent alone in preventing HE recurrence, and its favorable safety profile (essentially non-absorbed) makes it suitable for long-term use even in advanced cirrhosis.